Retrospective, observational study to compare the outcomes of patient receiving TAVI through transfemoral and transaxillary fully percutaneous approach adjusting for main baseline differences.
Aortic stenosis (AS) is the most frequently treated heart valve disease in our society. Transcatheter aortic valve implantation (TAVI) was originally described through an antegrade transeptal route by Cribier and colleagues in 2002. Because of the complexity of the procedure and risks of damaging the mitral apparatus, this approach was abandoned in favor of less challenging alternatives, with transfemoral (TF) route as primary option. Nevertheless, the TF approach is not feasible or of high risk in between 15 and 35% of the patients and vascular complications have been shown to be an independent predictor of death warranting alternative access techniques for TAVI. In this regard, the transapical, direct aortic, transcarotid, transcaval, and transubclavian/transaxillary (TSc) implantation routes currently serve as alternative access options. The TSc approach was initially used in selected cases. However, recent series suggest that TSc may provide better outcomes than alternative routes when TF is inadequate. Additionally, same studies suggest that, as compared to TF approach, TSc TAVI may present lower rate of vascular complications with comparable rates of other major outcomes despite the worse baseline profile of patients who are considered inappropriate for TF procedures. Moreover, fully-percutaneous TSc approach can be successfully performed with low rate of complications as was recently proposed by some authors. However, comparisons have been based in small series of cases, most of them with former iteration of TAVI devices, and a formal prospective comparison has never been performed. Therefore, our aim is to gather all cases of fully-percutaneous TSc and TF approaches for TAVI in Spain and Portugal and compare the standardized safety and efficacy endpoints through a matched analysis.
Study Type
OBSERVATIONAL
Enrollment
75
Transcatheter aortic valve implantation
Hospital Clínico Universitario de Valladolid
Valladolid, Spain
30-day death, stroke or embolic events, PVE or sepsis
Combined endpoint of death, stroke or embolic events, PVE or sepsis at 30-day follow up.
Time frame: 30 day
1-year death, stroke or embolic events, PVE or sepsis
Combined endpoint of death, stroke or embolic events, PVE or sepsis at 1-year follow up.
Time frame: 1 year
Intraprocedural Vascular complications
Intraprocedural Vascular complications
Time frame: Intraprocedural
In-hospital Vascular complications
In-hospital Vascular complications
Time frame: 7-days
Short term complications related to the approach.
Short term complications related to the approach.
Time frame: 30-days
Mid term complications related to the approach.
Mid term complications related to the approach.
Time frame: 1-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.